Volume 24 - Issue 5 - May 2016
News
06/02/2016
Click here to see the answer.
Click here to see the answer.
Click here to see the...
06/02/2016
The Dermatologist
Derm Dx
06/02/2016
David M. Lemchak; Oleg E. Akilov, MD, PhD
A 64-year-old man presented for management of his chronic skin condition on the scalp.
A 64-year-old man presented for management of his chronic skin condition on the scalp.
A 64-year-old man presented for...
06/02/2016
The Dermatologist
06/02/2016
Lisa B. Samalonis
This review looks at new research results and trends in therapies for skin cancer.
This review looks at new research results and trends in therapies for skin cancer.
This review looks at new...
06/02/2016
The Dermatologist
06/01/2016
Juvéderm Volbella XC (Allergan) received FDA approval for use in the lips for lip augmentation and for correction of perioral rhytids, or perioral lines, in adults over the age of 21.
Juvéderm Volbella XC (Allergan) received FDA approval for use in the lips for lip augmentation and for correction of perioral rhytids, or perioral lines, in adults over the age of 21.
Juvéderm Volbella XC (Allergan)...
06/01/2016
The Dermatologist
05/31/2016
Pfizer Inc. and Anacor Pharmaceuticals, Inc. have entered into a definitive merger agreement under which Pfizer will acquire Anacor.
Pfizer Inc. and Anacor Pharmaceuticals, Inc. have entered into a definitive merger agreement under which Pfizer will acquire Anacor.
Pfizer Inc. and Anacor...
05/31/2016
The Dermatologist
News
05/28/2016
Click here to see the answer.
Click here to see the answer.
Click here to see the answer.
05/28/2016
The Dermatologist
Spotlight
06/16/2016
Benjamin Barankin, MD, FRCPC
Charles E. Crutchfield III, MD, is a clinical professor of dermatology at the University of Minnesota Medical School.
Charles E. Crutchfield III, MD, is a clinical professor of dermatology at the University of Minnesota Medical School.
Charles E. Crutchfield III, MD,...
06/16/2016
The Dermatologist
FDA Alerts
05/27/2016
A recently-approved plaque psoriasis drug is predicted to generate sales more than $1 billion in the US and Europe.
A recently-approved plaque psoriasis drug is predicted to generate sales more than $1 billion in the US and Europe.
A recently-approved plaque...
05/27/2016
The Dermatologist
Research in Review
06/14/2016
Kenneth Beer, MD
One year after its approval, Dr Beer provides an update on clinical experience with deoxycholic acid (Kybella).
One year after its approval, Dr Beer provides an update on clinical experience with deoxycholic acid (Kybella).
One year after its approval, Dr...
06/14/2016
The Dermatologist
News
05/26/2016
A recent study evaluated detailed drug utilization in patients with psoriasis compared with controls in a population-based sample.
A recent study evaluated detailed drug utilization in patients with psoriasis compared with controls in a population-based sample.
A recent study evaluated...
05/26/2016
The Dermatologist
